From GLP-1 Agonism to Triple-Receptor Therapy. Narrative Review of Semaglutide, Tirzepatide, and Retatrutide in Obesity Management.
DOI:
https://doi.org/10.12775/QS.2026.54.70772Keywords
obesity, incretin-based therapy, GLP-1 receptor agonists, dual agonists, triple agonists, semaglutide, tirzepatide, retatrutideAbstract
Background: Obesity is a chronic multifactorial disease that affects a growing proportion of the global population. According to the WHO, obesity is now a global concern. From 1990 to 2022, the prevalence of obesity among minors increased from 2% to 8%, and among adults, it rose from 7% to 16%. The growing global prevalence of obesity has intensified the need for pharmacological therapies.
Aim: This narrative review presents the clinical efficacy, metabolic effects, and safety profiles of semaglutide, tirzepatide, and retatrutide, with particular emphasis on their underlying mechanisms of action.
Materials and Methods: A narrative review was conducted based on key randomised controlled trials, including the STEP, SURMOUNT, and phase II retatrutide programs. Data on weight reduction, metabolic parameters, and adverse events were extracted and analysed. Mechanistic insights were integrated to interpret differences in clinical outcomes.
Results: All three therapies produced significant weight reduction and metabolic improvements, with efficacy increasing in relation to the number of targeted receptors. Semaglutide resulted in a weight loss of up to 16.0%, tirzepatide achieved a reduction of 20.9%, and retatrutide demonstrated the highest efficacy, with a weight loss of 24.2%. All agents were associated with improvements in cardiac, glycemic, and lipid profiles. Gastrointestinal adverse events were frequent and dose-dependent, resulting in higher discontinuation rates at higher doses.
Conclusions: Incretin agonists represent a significant advancement in obesity pharmacotherapy, with multi-receptor targeting translating into superior metabolic outcomes. Retatrutide demonstrates the highest potential efficacy among studied agents, although further phase III data are required. These findings support the concept that obesity is a chronic disease that requires long-term treatment and highlight the growing role of mechanism-based pharmacotherapy in its management.
References
Aronne, L. J., Sattar, N., Horn, D. B., Bays, H. E., Wharton, S., Lin, W.-Y., Ahmad, N. N., Zhang, S., Liao, R., Bunck, M. C., Jouravskaya, I., Murphy, M. A., SURMOUNT-4 Investigators, Fretes, J. O., Coronel, M. J., Gutnisky, L. L., Frechtel, G. D., Gelersztein, E., Aizenberg, D., … Nardandrea, J. P. (2024). Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA, 331(1), 38. https://doi.org/10.1001/jama.2023.24945
Arterburn, D. E., Maciejewski, M. L., & Tsevat, J. (2005). Impact of morbid obesity on medical expenditures in adults. International Journal of Obesity, 29(3), 334–339. https://doi.org/10.1038/sj.ijo.0802896
Bjørge, T., Häggström, C., Ghaderi, S., Nagel, G., Manjer, J., Tretli, S., Ulmer, H., Harlid, S., Rosendahl, A. H., Lang, A., Stattin, P., Stocks, T., & Engeland, A. (2019). BMI and weight changes and risk of obesity-related cancers: A pooled European cohort study. International Journal of Epidemiology, 48(6), 1872–1885. https://doi.org/10.1093/ije/dyz188
Brønden, A., Naver, S. V., Knop, F. K., & Christensen, M. (2015). Albiglutide for treating type 2 diabetes: An evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy. Expert Opinion on Drug Metabolism & Toxicology, 11(9), 1493–1503. https://doi.org/10.1517/17425255.2015.1068288
Buchan, A. M. J., Polak, J. M., Capella, C., Solcia, E., & Pearse, A. G. E. (1978). Electronimmunocytochemical evidence for the K cell localization of gastric inhibitory polypeptide (GIP) im man. Histochemistry, 56(1), 37–44. https://doi.org/10.1007/BF00492251
Buckley, S. T., Bækdal, T. A., Vegge, A., Maarbjerg, S. J., Pyke, C., Ahnfelt-Rønne, J., Madsen, K. G., Schéele, S. G., Alanentalo, T., Kirk, R. K., Pedersen, B. L., Skyggebjerg, R. B., Benie, A. J., Strauss, H. M., Wahlund, P.-O., Bjerregaard, S., Farkas, E., Fekete, C., Søndergaard, F. L., … Knudsen, L. B. (2018). Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Science Translational Medicine, 10(467), eaar7047. https://doi.org/10.1126/scitranslmed.aar7047
Campbell, J. E., & Drucker, D. J. (2013). Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action. Cell Metabolism, 17(6), 819–837. https://doi.org/10.1016/j.cmet.2013.04.008
Coskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., Kuchibhotla, U., Moyers, J. S., Benson, C. T., Gimeno, R. E., D’Alessio, D. A., & Haupt, A. (2018). LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Molecular Metabolism, 18, 3–14. https://doi.org/10.1016/j.molmet.2018.09.009
Coskun, T., Urva, S., Roell, W. C., Qu, H., Loghin, C., Moyers, J. S., O’Farrell, L. S., Briere, D. A., Sloop, K. W., Thomas, M. K., Pirro, V., Wainscott, D. B., Willard, F. S., Abernathy, M., Morford, L., Du, Y., Benson, C., Gimeno, R. E., Haupt, A., & Milicevic, Z. (2022). LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metabolism, 34(9), 1234-1247.e9. https://doi.org/10.1016/j.cmet.2022.07.013
Courcoulas, A. P. (2013). Weight Change and Health Outcomes at 3 Years After Bariatric Surgery Among Individuals With Severe Obesity. JAMA. https://doi.org/10.1001/jama.2013.280928
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., & Lingvay, I. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): A randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/S0140-6736(21)00213-0
Day, J. W., Ottaway, N., Patterson, J. T., Gelfanov, V., Smiley, D., Gidda, J., Findeisen, H., Bruemmer, D., Drucker, D. J., Chaudhary, N., Holland, J., Hembree, J., Abplanalp, W., Grant, E., Ruehl, J., Wilson, H., Kirchner, H., Lockie, S. H., Hofmann, S., … Tschöp, M. H. (2009). A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nature Chemical Biology, 5(10), 749–757. https://doi.org/10.1038/nchembio.209
Dutta, D., Surana, V., Singla, R., Aggarwal, S., & Sharma, M. (2021). Efficacy and safety of novel twincretin tirzepatide a dual GIP and GLP-1 receptor agonist in the management of type-2 diabetes: A Cochrane meta-analysis. Indian Journal of Endocrinology and Metabolism, 25(6), 475–489. https://doi.org/10.4103/ijem.ijem_423_21
Eissele, R., Göke, R., Willemer, S., Harthus, H. ‐P., Vermeer, H., Arnold, R., & Göke, B. (1992). Glucagon‐like peptide‐1 cells in the gastrointestinal tract and pancreas of rat, pig and man. European Journal of Clinical Investigation, 22(4), 283–291. https://doi.org/10.1111/j.1365-2362.1992.tb01464.x
Enyew Belay, K., Jemal, R. H., & Tuyizere, A. (2024). Innovative Glucagon-based Therapies for Obesity. Journal of the Endocrine Society, 8(12), bvae197. https://doi.org/10.1210/jendso/bvae197
Felson, D. T., Zhang, Y., Hannan, M. T., Naimark, A., Weissman, B., Aliabadi, P., & Levy, D. (1997). Risk factors for incident radiographic knee osteoarthritis in the elderly. The framingham study. Arthritis & Rheumatism, 40(4), 728–733. https://doi.org/10.1002/art.1780400420
Finan, B., Yang, B., Ottaway, N., Smiley, D. L., Ma, T., Clemmensen, C., Chabenne, J., Zhang, L., Habegger, K. M., Fischer, K., Campbell, J. E., Sandoval, D., Seeley, R. J., Bleicher, K., Uhles, S., Riboulet, W., Funk, J., Hertel, C., Belli, S., … Tschöp, M. H. (2015). A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nature Medicine, 21(1), 27–36. https://doi.org/10.1038/nm.3761
Finkelstein, E., Fiebelkorn, I. C., & Wang, G. (2005). The Costs of Obesity among Full-Time Employees. American Journal of Health Promotion, 20(1), 45–51. https://doi.org/10.4278/0890-1171-20.1.45
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519
Garvey, W. T., Frias, J. P., Jastreboff, A. M., Le Roux, C. W., Sattar, N., Aizenberg, D., Mao, H., Zhang, S., Ahmad, N. N., Bunck, M. C., Benabbad, I., Zhang, X. M., Abalos, F. H., Manghi, F. C. P., Zaidman, C. J., Vico, M. L., Aizenberg, D., Costanzo, P. R., Serra, L. P., … Jones, T. (2023). Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): A double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. The Lancet, 402(10402), 613–626. https://doi.org/10.1016/S0140-6736(23)01200-X
Gault, V. A., Bhat, V. K., Irwin, N., & Flatt, P. R. (2013). A Novel Glucagon-like Peptide-1 (GLP-1)/Glucagon Hybrid Peptide with Triple-acting Agonist Activity at Glucose-dependent Insulinotropic Polypeptide, GLP-1, and Glucagon Receptors and Therapeutic Potential in High Fat-fed Mice. Journal of Biological Chemistry, 288(49), 35581–35591. https://doi.org/10.1074/jbc.M113.512046
Haase, C. L., Eriksen, K. T., Lopes, S., Satylganova, A., Schnecke, V., & McEwan, P. (2021). Body mass index and risk of obesity‐related conditions in a cohort of 2.9 million people: Evidence from a UK primary care database. Obesity Science & Practice, 7(2), 137–147. https://doi.org/10.1002/osp4.474
I˙meryüz, N., Yeğen, B. Ç., Bozkurt, A., Coşkun, T., Villanueva-Peñacarrillo, M. L., & Ulusoy, N. B. (1997). Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. American Journal of Physiology-Gastrointestinal and Liver Physiology, 273(4), G920–G927. https://doi.org/10.1152/ajpgi.1997.273.4.G920
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2023). Triple–Hormone-Receptor Agonist Retatrutide for Obesity—A Phase 2 Trial. New England Journal of Medicine, 389(6), 514–526. https://doi.org/10.1056/NEJMoa2301972
Jimenez-Solem, E., Rasmussen, M. H., Christensen, M., & Knop, F. K. (2010). Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes. Current Opinion in Molecular Therapeutics, 12(6), 790–797.
Jordan, J. M., Helmick, C. G., Renner, J. B., Luta, G., Dragomir, A. D., Woodard, J., Fang, F., Schwartz, T. A., Abbate, L. M., Callahan, L. F., Kalsbeek, W. D., & Hochberg, M. C. (2007). Prevalence of knee symptoms and radiographic and symptomatic knee osteoarthritis in African Americans and Caucasians: The Johnston County Osteoarthritis Project. The Journal of Rheumatology, 34(1), 172–180.
Kowalska, M. K., El-Mallul, A., Hudecka, W., Lubojańska, J. E., Lubojański, P. J., Orłowska, S. M., & Bednarczyk, Ł. (2026). The Multifaceted Nature of GLP-1: Molecular Mechanisms and Signaling Pathways in Metabolic and Neurodegenerative Diseases. International Journal of Molecular Sciences, 27(4), 1886. https://doi.org/10.3390/ijms27041886
Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L. B., McGuire, J., Steensgaard, D. B., Strauss, H. M., Gram, D. X., Knudsen, S. M., Nielsen, F. S., Thygesen, P., Reedtz-Runge, S., & Kruse, T. (2015). Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. Journal of Medicinal Chemistry, 58(18), 7370–7380. https://doi.org/10.1021/acs.jmedchem.5b00726
Li, W., Zhou, Q., Cong, Z., Yuan, Q., Li, W., Zhao, F., Xu, H. E., Zhao, L.-H., Yang, D., & Wang, M.-W. (2024). Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. Cell Discovery, 10(1), 77. https://doi.org/10.1038/s41421-024-00700-0
Lu, Y., Hajifathalian, K., Ezzati, M., Woodward, M., Rimm, E. B., & Danaei, G. (2014). Metabolic mediators of the effects of body-mass index, overweight, and obesity on coronary heart disease and stroke: A pooled analysis of 97 prospective cohorts with 1·8 million participants. The Lancet, 383(9921), 970–983. https://doi.org/10.1016/S0140-6736(13)61836-X
Melson, E., Ashraf, U., Papamargaritis, D., & Davies, M. J. (2025). What is the pipeline for future medications for obesity? International Journal of Obesity, 49(3), 433–451. https://doi.org/10.1038/s41366-024-01473-y
Phelps, N. H., Singleton, R. K., Zhou, B., Heap, R. A., Mishra, A., Bennett, J. E., Paciorek, C. J., Lhoste, V. P., Carrillo-Larco, R. M., Stevens, G. A., Rodriguez-Martinez, A., Bixby, H., Bentham, J., Di Cesare, M., Danaei, G., Rayner, A. W., Barradas-Pires, A., Cowan, M. J., Savin, S., … Ezzati, M. (2024). Worldwide trends in underweight and obesity from 1990 to 2022: A pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. The Lancet, 403(10431), 1027–1050. https://doi.org/10.1016/S0140-6736(23)02750-2
Pocai, A., Carrington, P. E., Adams, J. R., Wright, M., Eiermann, G., Zhu, L., Du, X., Petrov, A., Lassman, M. E., Jiang, G., Liu, F., Miller, C., Tota, L. M., Zhou, G., Zhang, X., Sountis, M. M., Santoprete, A., Capito’, E., Chicchi, G. G., … SinhaRoy, R. (2009). Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice. Diabetes, 58(10), 2258–2266. https://doi.org/10.2337/db09-0278
Powell-Wiley, T. M., Poirier, P., Burke, L. E., Després, J.-P., Gordon-Larsen, P., Lavie, C. J., Lear, S. A., Ndumele, C. E., Neeland, I. J., Sanders, P., St-Onge, M.-P., & On behalf of the American Heart Association Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Epidemiology and Prevention; and Stroke Council. (2021). Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation, 143(21). https://doi.org/10.1161/CIR.0000000000000973
Rodriguez, L. A., Kanaya, A. M., Shiboski, S. C., Fernandez, A., Herrington, D., Ding, J., & Bradshaw, P. T. (2021). Does NAFLD mediate the relationship between obesity and type 2 diabetes risk? Evidence from the multi-ethnic study of atherosclerosis (MESA). Annals of Epidemiology, 63, 15–21. https://doi.org/10.1016/j.annepidem.2021.07.005
Rosenstock, J., Frias, J., Jastreboff, A. M., Du, Y., Lou, J., Gurbuz, S., Thomas, M. K., Hartman, M. L., Haupt, A., Milicevic, Z., & Coskun, T. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: A randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. The Lancet, 402(10401), 529–544. https://doi.org/10.1016/S0140-6736(23)01053-X
Samms, R. J., Coghlan, M. P., & Sloop, K. W. (2020). How May GIP Enhance the Therapeutic Efficacy of GLP-1? Trends in Endocrinology & Metabolism, 31(6), 410–421. https://doi.org/10.1016/j.tem.2020.02.006
Sanyal, A. J., Kaplan, L. M., Frias, J. P., Brouwers, B., Wu, Q., Thomas, M. K., Harris, C., Schloot, N. C., Du, Y., Mather, K. J., Haupt, A., & Hartman, M. L. (2024). Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: A randomized phase 2a trial. Nature Medicine, 30(7), 2037–2048. https://doi.org/10.1038/s41591-024-03018-2
Sun, B., Willard, F. S., Feng, D., Alsina-Fernandez, J., Chen, Q., Vieth, M., Ho, J. D., Showalter, A. D., Stutsman, C., Ding, L., Suter, T. M., Dunbar, J. D., Carpenter, J. W., Mohammed, F. A., Aihara, E., Brown, R. A., Bueno, A. B., Emmerson, P. J., Moyers, J. S., … Sloop, K. W. (2022). Structural determinants of dual incretin receptor agonism by tirzepatide. Proceedings of the National Academy of Sciences, 119(13), e2116506119. https://doi.org/10.1073/pnas.2116506119
Sun, M., Da Silva, M., Bjørge, T., Fritz, J., Mboya, I. B., Jerkeman, M., Stattin, P., Wahlström, J., Michaëlsson, K., Van Guelpen, B., Magnusson, P. K. E., Sandin, S., Yin, W., Lagerros, Y. T., Ye, W., Nwaru, B., Kankaanranta, H., Lönnberg, L., Chabok, A., … Stocks, T. (2024). Body mass index and risk of over 100 cancer forms and subtypes in 4.1 million individuals in Sweden: The Obesity and Disease Development Sweden (ODDS) pooled cohort study. The Lancet Regional Health - Europe, 45, 101034. https://doi.org/10.1016/j.lanepe.2024.101034
Thomas, M. K., Nikooienejad, A., Bray, R., Cui, X., Wilson, J., Duffin, K., Milicevic, Z., Haupt, A., & Robins, D. A. (2021). Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. The Journal of Clinical Endocrinology and Metabolism, 106(2), 388–396. https://doi.org/10.1210/clinem/dgaa863
Wadden, T. A., Bailey, T. S., Billings, L. K., Davies, M., Frias, J. P., Koroleva, A., Lingvay, I., O’Neil, P. M., Rubino, D. M., Skovgaard, D., Wallenstein, S. O. R., Garvey, W. T., & STEP 3 Investigators. (2021). Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA, 325(14), 1403. https://doi.org/10.1001/jama.2021.1831
Wadden, T. A., Chao, A. M., Machineni, S., Kushner, R., Ard, J., Srivastava, G., Halpern, B., Zhang, S., Chen, J., Bunck, M. C., Ahmad, N. N., & Forrester, T. (2023). Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: The SURMOUNT-3 phase 3 trial. Nature Medicine, 29(11), 2909–2918. https://doi.org/10.1038/s41591-023-02597-w
Wang, S. H., Keenan, B. T., Wiemken, A., Zang, Y., Staley, B., Sarwer, D. B., Torigian, D. A., Williams, N., Pack, A. I., & Schwab, R. J. (2020). Effect of Weight Loss on Upper Airway Anatomy and the Apnea–Hypopnea Index. The Importance of Tongue Fat. American Journal of Respiratory and Critical Care Medicine, 201(6), 718–727. https://doi.org/10.1164/rccm.201903-0692OC
Welsh, A., Hammad, M., Piña, I. L., & Kulinski, J. (2024). Obesity and cardiovascular health. European Journal of Preventive Cardiology, 31(8), 1026–1035. https://doi.org/10.1093/eurjpc/zwae025
Wharton, S., Freitas, P., Hjelmesæth, J., Kabisch, M., Kandler, K., Lingvay, I., Quiroga, M., Rosenstock, J., & Garvey, W. T. (2025). Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): A randomised, controlled, phase 3b trial. The Lancet Diabetes & Endocrinology, 13(11), 949–963. https://doi.org/10.1016/S2213-8587(25)00226-8
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
Wilding, J. P. H., Batterham, R. L., Davies, M., Van Gaal, L. F., Kandler, K., Konakli, K., Lingvay, I., McGowan, B. M., Oral, T. K., Rosenstock, J., Wadden, T. A., Wharton, S., Yokote, K., Kushner, R. F., & STEP 1 Study Group. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism, 24(8), 1553–1564. https://doi.org/10.1111/dom.14725
World Health Organization. (n.d.). Obesity. World Health Organization. Retrieved March 18, 2026, from https://www.who.int/health-topics/obesity
Zelber-Sagi, S., Lotan, R., Shlomai, A., Webb, M., Harrari, G., Buch, A., Nitzan Kaluski, D., Halpern, Z., & Oren, R. (2012). Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up. Journal of Hepatology, 56(5), 1145–1151. https://doi.org/10.1016/j.jhep.2011.12.011
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Jerzy Darmoń, Joanna Makowska, Karolina Domańska, Natalia Piegza, Anna Sieczka, Maria Windyga, Krzysztof Paweł Darmoń, Aleksandra Papuga, Makary Hejduk
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 9
Number of citations: 0
